ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,021.63
0.57%
US Tech 100
20,355.20
0.45%
Dow Jones
44,860.31
0.28%
Brent Oil
72.225
-0.31%
Bitcoin
92,905.24
1.01%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Aptose Biosciences Inc (APTO)

  7. Aptose Biosciences Inc (APTO) News

APTO

Aptose Biosciences (APTO)

Aptose Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:APTO
DateTimeSourceHeadlineSymbolCompany
11/26/20246:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APTOAptose Biosciences Inc
11/25/20244:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
11/25/20244:15PMGlobeNewswire Inc.Aptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNASDAQ:APTOAptose Biosciences Inc
11/25/20246:05AMEdgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APTOAptose Biosciences Inc
11/22/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
11/22/20248:00AMGlobeNewswire Inc.Aptose Biosciences Inc. Announces Pricing of $8 Million Public OfferingNASDAQ:APTOAptose Biosciences Inc
11/22/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APTOAptose Biosciences Inc
11/20/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
11/20/20247:30AMGlobeNewswire Inc.Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNASDAQ:APTOAptose Biosciences Inc
11/14/20243:22PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:APTOAptose Biosciences Inc
11/08/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
11/08/20244:01PMGlobeNewswire Inc.Aptose Reports Results for the Third Quarter 2024NASDAQ:APTOAptose Biosciences Inc
10/31/20246:39AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:APTOAptose Biosciences Inc
10/04/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
09/06/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
09/05/20244:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
09/05/20244:15PMGlobeNewswire Inc.Aptose Announces Results from Special Meeting of ShareholdersNASDAQ:APTOAptose Biosciences Inc
08/30/20244:35PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
08/30/20244:30PMGlobeNewswire Inc.Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop TuspetinibNASDAQ:APTOAptose Biosciences Inc
08/15/20244:35PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
08/15/20244:30PMGlobeNewswire Inc.Aptose Announces Adjournment of its Special Meeting of ShareholdersNASDAQ:APTOAptose Biosciences Inc
08/08/20245:22PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APTOAptose Biosciences Inc
08/08/20245:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
08/08/20245:06PMGlobeNewswire Inc.Aptose Reports Results for the Second Quarter 2024NASDAQ:APTOAptose Biosciences Inc
07/26/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
07/19/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
07/19/20245:00PMGlobeNewswire Inc.Aptose Announces Receipt of Deficiency Notice from NasdaqNASDAQ:APTOAptose Biosciences Inc
07/17/202411:43AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:APTOAptose Biosciences Inc
06/14/20247:40AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
06/03/20244:35PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:APTO

Your Recent History

NASDAQ
SAVA
Cassava Sciences
USOTC
CBDW
1606 (PK)
USOTC
MONI
Moon Equity (PK)
NASDAQ
ENTA
Enanta Pharmaceuticals
NASDAQ
AVXL
Anavex Life Sciences
USOTC
DBMM
Digital Brand Media and ... (PK)
NYSE
AMC
AMC Entertainment
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
ERHE
ERHC Energy (CE)
USOTC
GDVM
Global Developments (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
HIRU
Hiru (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
NASDAQ
LWLG
Lightwave Logic
NASDAQ
NB
NioCorp Developments
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Big Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2276.64 only $796.82